Russia Radiotherapy Market Overview, 2031

Key Insights

• The Russian radiotherapy market operates within a predominantly public healthcare system, with the state sector accounting for an estimated 80–85% of services delivered through compulsory medical insurance and federal/regional budgets . Cancer remains a leading cause of mortality, with approximately 600,000 new cases registered annually and 250,000–300,000 radiotherapy courses performed each year .
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, with linear accelerators comprising approximately 90% of the entire radiotherapy equipment fleet . The installed base of 500–600 units for radiotherapy treatment is characterised by significant obsolescence over half of all installations require modernisation or replacement .
• Radiotherapy systems and equipment represent the largest offering segment, with the market demonstrating stable growth of 7–10% annually in recent years . Major international suppliers including Varian Medical Systems and Elekta maintain strong market positions through public procurement contracts and service agreements, though domestic manufacturing initiatives are emerging .
• Hospitals and integrated cancer centres are the largest end-user segment, operating within the public healthcare system. However, geographic distribution is highly concentrated in major cities Moscow, St. Petersburg, Novosibirsk, Yekaterinburg, and Kazan with only 30–40% of Russian regions possessing their own centres with modern equipment .
• Regulatory oversight is provided by the Ministry of Health under Order No. 116n (2021), which establishes the procedure for providing medical care to adults with oncological diseases, including radiotherapy . The government's federal project "Fight against Oncological Diseases" provides the strategic framework for infrastructure modernisation, with the radiological service undergoing large-scale transformation beginning in 2025 .

Market Outlook

• According to the research report, "Russia Radiotherapy Market Overview, 2031," published by Bonafide Research, the Russia Radiotherapy market is anticipated to grow at more than 7.20% CAGR from 2026 to 2031. This growth trajectory reflects sustained government investment in cancer care infrastructure, ongoing equipment modernisation programmes, and increasing cancer burden across the population.
• The market is expected to benefit from significant public sector investment. In 2025, a large-scale transformation of the radiological service was initiated, with 286 units of equipment including 46 "heavy" units scheduled for installation in 2026 . Over the past seven years of national project implementation, 16,000 units of medical equipment have been introduced, including over 1,000 "heavy" units, with 18 modern oncology facilities constructed and additional centres under development .
• Technology modernisation is accelerating. The Russian government's federal project "Fight against Oncological Diseases" aims to increase life expectancy by improving the accessibility and quality of medical care, with specific targets including expanding follow-up care coverage to 90% . The volume of antitumour therapy has grown by 97.5% over six years, with radiotherapy increasing by 51% .
• Domestic manufacturing is emerging as a significant market factor. RESHETNEV company (part of ROSCOSMOS), in cooperation with Tomsk Polytechnic University, has produced two Mobile Radiation Oncology Suite prototypes for intraoperative radiotherapy, with plans for serial production commencing in 2026 . Rosatom is developing "Brachium 2.0," a next-generation brachytherapy device with 96% domestic components, scheduled for release by 2029 .
• Long-term growth is supported by demographic trends and sustained federal investment. The modernisation programme has extended to regions in 2026, with the Ministry of Health reporting that the radiological service transformation aims to strengthen material and technical infrastructure across federal and regional healthcare organisations .

Market Dynamics

Driver: Sustained Government Investment and National Oncology Programmes
The primary driver of the Russian radiotherapy market is sustained government investment through national projects and federal programmes. The federal project "Fight against Oncological Diseases" provides the strategic framework for oncology care modernisation, with key objectives including increasing early detection of malignant tumours, reducing one-year mortality rates, and expanding follow-up care coverage . Over seven years of national project implementation, 16,000 units of medical equipment have been introduced, including more than 1,000 "heavy" units . In 2025, the large-scale transformation of the radiological service was initiated, with federal organisations equipped and regional modernisation commencing in 2026 totalling 286 units of equipment scheduled for installation, of which 46 are "heavy" units . The volume of antitumour therapy has grown by 97.5% over six years, with radiotherapy increasing by 51%, demonstrating the sustained commitment to expanding cancer care capacity .

Challenge: Equipment Obsolescence and Infrastructure Constraints
A significant challenge facing the Russian radiotherapy market is the substantial proportion of obsolete equipment. Over half of the 500–600 radiotherapy installations in Russia require modernisation or replacement . Equipment is heavily concentrated in major cities Moscow, St. Petersburg, Novosibirsk, Yekaterinburg, and Kazan with only 30–40% of Russian regions possessing their own centres with modern equipment . Patients from remote regions are forced to travel to federal centres for treatment, creating access disparities. In government institutions, equipment operates at maximum capacity 8 to 12 hours daily creating queues and increasing waiting times . The average cost of a radiotherapy course for the state budget is 150,000–300,000 rubles, while private clinic prices range from 200,000–500,000 rubles for standard LINAC treatment and 1.5–3 million rubles for proton therapy . Regulatory compliance presents additional challenges, with the Ministry of Health postponing the deadline for radiotherapy departments to meet new requirements from 2026 to 2030 for facilities created before 2022, acknowledging infrastructure constraints .



Trend: Domestic Manufacturing and Technology Localisation
A major trend shaping the Russian radiotherapy market is the emergence of domestic manufacturing and technology localisation initiatives. RESHETNEV company (part of ROSCOSMOS), in cooperation with Tomsk Polytechnic University and leading medical institutions including Sechenov First Moscow State Medical University, has produced two Mobile Radiation Oncology Suite prototypes for intraoperative radiotherapy . The suite, based on domestically designed induction accelerator technology, enables spot treatment of tumours with minimal damage to surrounding tissue. Serial production is planned to commence in 2026, with domestic production eliminating the need for imported components and reducing equipment costs . Rosatom is developing "Brachium 2.0," a next-generation brachytherapy device with 96% domestic components and a new iridium-based isotope source, scheduled for release by 2029 . The current version of the Brachium complex is already available in Russian medical institutions . This trend toward domestic manufacturing reduces dependency on international suppliers and creates new market opportunities for domestic equipment and service providers.

Policies

• The Ministry of Health's Order No. 116n (19 February 2021) establishes the procedure for providing medical care to the adult population with oncological diseases, including requirements for radiotherapy services. However, the deadline for organisations created before 2022 to meet new requirements has been postponed to 1 January 2030 .
• The federal project "Fight against Oncological Diseases" provides the strategic framework for cancer care modernisation, with key goals including increasing early detection of malignant tumours, reducing one-year mortality rates (which reached a historical minimum of 16.7% in 2025), and expanding follow-up care coverage .
• The Ministry of Health's radiological service transformation programme, initiated in 2025, involves equipping federal organisations and, from 2026, regional healthcare facilities with modern radiotherapy equipment .
• Rosatom's nuclear industry participates in radiotherapy equipment development, with the "Brachium 2.0" brachytherapy device programme aiming to achieve 96% domestic component content and international market expansion .
• The Ministry of Health is pursuing legal and regulatory harmonisation for radiology and radiotherapy specialties. A 2025 academic analysis identified significant confusion surrounding definitions of fundamental terms and concepts, proposing development of unified terminology, establishment of professional standards, and creation of a chief external radiotherapist position .
• Public procurement for radiotherapy equipment and services is conducted through electronic auctions under Federal Law 44-FZ, with major procurements including the Moscow Hertsen Oncology Institute's 31 million ruble tender for Halcyon LINAC repair and the Tula Oncology Dispensary's 7.18 million ruble tender for Elekta LINAC spare parts .

Segment Analysis

Russia Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment, with linear accelerators comprising approximately 90% of the entire radiotherapy equipment fleet . The installed base of 500–600 units includes conventional LINACs from Varian Medical Systems and Elekta, with recent procurements including the Halcyon system at the Moscow Hertsen Oncology Institute . The segment is driven by the clinical dominance of IMRT, IGRT, and SBRT techniques. The Tula Oncology Dispensary's Elekta LINAC demonstrates the application of computer-guided treatment delivery, enabling high radiation doses to tumours while sparing healthy tissue .
• Internal / Brachytherapy: This segment is clinically essential, particularly for gynaecological and urological cancers. Rosatom is developing "Brachium 2.0," a next-generation brachytherapy device with a new iridium-based isotope source, reduced weight, and refined software . The current Brachium complex is available in Russian medical institutions and features dosimetric control, applicators compatible with CT and MRI, and 3D treatment planning capabilities .
• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. The Ministry of Health has drafted a proposal to include cancer vaccines in the programme of free medical care beginning in 2026, including the peptide vaccine Oncopept for colorectal cancer, personalised mRNA vaccine therapy, and T-cell immunotherapy . The Russian government has committed to ensuring availability of these advanced therapies across all regions .

Russia Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by the high capital cost of linear accelerators and sustained government investment. Major international suppliers active in the Russian market include Varian Medical Systems (Halcyon LINACs) and Elekta . Recent procurement includes the Moscow Hertsen Oncology Institute's 31 million ruble tender for Halcyon LINAC repair and the Tula Oncology Dispensary's 7.18 million ruble tender for Elekta LINAC spare parts . Domestic manufacturing is emerging, with RESHETNEV planning serial production of Mobile Radiation Oncology Suites in 2026 . Equipment renewal cycles and infrastructure modernisation drive sustained demand.
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems, with the Brachium complex featuring 3D treatment planning capabilities for precise tumour irradiation . The services component encompasses installation, comprehensive maintenance, clinical training, and technical support. Public procurement for LINAC repair services demonstrates significant ongoing service expenditure, with the Moscow Hertsen Institute's contract valued at 31 million rubles and the Tula Oncology Dispensary's spare parts procurement valued at 7.18 million rubles .

Russia Radiotherapy Market By Application
• Breast Cancer: This is a major application segment, with breast cancer ranking among the most frequent malignancies in Russia. Radiotherapy plays a central role in breast-conserving therapy and post-mastectomy treatment.
• Prostate Cancer: A significant application area, with widespread use of EBRT and brachytherapy. Brachium brachytherapy systems are utilised for localised tumours, including prostate cancer .
• Lung Cancer: This segment is growing, with increased adoption of advanced EBRT techniques.
• Head & Neck Cancer: This is a critical application due to anatomical complexity, requiring highly conformal radiation delivery.
• Central Nervous System / Brain: This is a significant application, with stereotactic radiosurgery for brain metastases and primary CNS tumours.
• Gastro-intestinal: This segment is expanding with the development of novel therapies, including the peptide vaccine Oncopept for colorectal cancer .
• Other Applications: Includes gynaecological cancers, with brachytherapy playing a critical role, and paediatric cancers, with the Reshetnev MROS designed for various cancerous growths .

Russia Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the public healthcare system. Major centres include the Moscow Hertsen Oncology Institute, which procured Halcyon LINAC repair services , and the Tula Oncology Dispensary, which operates an Elekta LINAC . The Tomsk National Medical Research Centre and Sechenov University are partners in the Reshetnev MROS project . These institutions manage complex equipment fleets and are the primary beneficiaries of federal and regional investment programmes.
• Standalone Radiotherapy Centres: This segment is growing, particularly in private healthcare, with demand supported by rising household affordability and development of voluntary medical insurance programmes . Private clinics offer radiotherapy courses at 200,000–500,000 rubles for LINAC treatment and 1.5–3 million rubles for proton therapy .
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their role in advancing the field. Institutions including the Oncology Research Institute of the Tomsk National Medical Research Centre and Sechenov First Moscow State Medical University are partners in domestic technology development, including the Reshetnev MROS project .
• Other Healthcare Facilities: Includes regional oncology dispensaries and community hospitals. Access remains limited in remote regions, with only 30–40% of Russian regions possessing modern equipment . The federal modernisation programme aims to address this disparity through regional equipment deployment .

Russia Radiotherapy Market Economics

• The Russian radiotherapy market was estimated in the range of 50–70 billion rubles in 2023 and 65–80 billion rubles in 2024, with 80–85% of this volume attributed to the state sector funded by compulsory medical insurance and federal/regional budgets .
• Service contract pricing and maintenance costs vary by equipment type and age. Public procurement for LINAC repair services demonstrates significant ongoing expenditure, with the Moscow Hertsen Institute's Halcyon repair contract valued at 31 million rubles and the Tula Oncology Dispensary's spare parts procurement at 7.18 million rubles .
• In the state sector, the average cost of a radiotherapy course for the budget is 150,000–300,000 rubles depending on equipment type and treatment complexity. Private clinics charge significantly higher prices: 200,000–500,000 rubles for standard LINAC treatment and 1.5–3 million rubles for proton therapy .
• Equipment downtime directly affects patient access and treatment outcomes. In government institutions, equipment operates at maximum capacity 8 to 12 hours daily creating queues and increasing waiting times .
• Domestic manufacturing is expected to reduce equipment and maintenance costs. Reshetnev's Mobile Radiation Oncology Suite, based on domestic technology, eliminates the need for imported components and reduces procurement, operation, and maintenance costs . Rosatom's Brachium 2.0 achieves 96% domestic component content .
• The economic impact of federal investment programmes is substantial. The radiological service transformation includes 286 units of equipment in 2026, including 46 "heavy" units, representing significant capital investment across regions .

Market Outlook by Infrastructure, Investment and Industry Development

• The federal project "Fight against Oncological Diseases" continues through 2030, with key goals including increasing life expectancy by improving the accessibility and quality of medical care, reducing one-year mortality rates, and expanding follow-up care coverage . In 2025, one-year mortality reached a historical minimum of 16.7%, and early-stage cancer detection reached 61.4% .
• The Ministry of Health's radiological service transformation, initiated in 2025, involves equipping federal organisations with modern equipment, with regional modernisation commencing in 2026. A total of 286 units of equipment are scheduled for installation in 2026, including 46 "heavy" units .
• Domestic manufacturing is emerging as a significant market factor. Reshetnev (part of ROSCOSMOS) has produced two Mobile Radiation Oncology Suite prototypes and plans serial production in 2026 . Rosatom is developing "Brachium 2.0" brachytherapy devices with 96% domestic components, scheduled for release by 2029 .
• Infrastructure expansion continues, with 18 modern oncology facilities constructed over seven years and additional centres under development . Geographic disparities remain significant: most centres are concentrated in major cities, and only 30–40% of regions have their own modern equipment .
• Digital transformation is enabling advanced treatment planning and precision radiotherapy. The Brachium complex features 3D treatment planning for precise tumour irradiation . The federal project emphasises active digitalisation of pathological anatomy and development of telemedicine capabilities .
• Workforce development and regulatory harmonisation are priorities. A 2025 academic analysis identified the need for unified terminology, professional standards for radiologists and radiotherapists, and establishment of a chief external radiotherapist position to improve quality of care and medical service funding .
• The long-term outlook remains positive as cancer incidence continues to rise, sustained government investment through the federal oncology project drives equipment modernisation, and domestic manufacturing reduces dependency on international suppliers. The market demonstrates stable 7–10% annual growth, supported by the development of national programmes and increasing awareness of radiotherapy's role in cancer treatment.



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities